查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1494746

2030 年胰臟癌市場預測：按治療類型、診斷工具、最終用戶和地區進行的全球分析

Pancreatic Cancer Market Forecasts to 2030 - Global Analysis By Treatment Type, Diagnostic Tool (Computerized Tomography Scans, Magnetic Resonance Imaging, Positron Emission Tomography Scans and Other Diagnostic Tools), End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球胰臟癌市場規模為 34.2 億美元，預計預測期內複合年成長率為 17.8%，到 2030 年將達到 91.3 億美元。

胰臟癌是一種在胰臟組織中發生的惡性，胰臟是位於胃後面的器官。其特徵是胰臟細胞異常且不受控制地生長，導致腫瘤的形成。胰臟癌通常難以早期發現，導致其死亡率很高。症狀可能直到疾病晚期才會出現，可能包括腹痛、黃疸、不明原因的體重減輕和消化器官系統問題。

根據美國癌症協會估計，到 2023 年，預計將有約 64,050 人被診斷出患有胰腺癌，約 50,550 人將死於胰腺癌。

病人支持團體的積極參與

患者倡導團體的積極參與透過提高意識、推動研究舉措和影響政策變化，在加強胰腺癌市場方面發揮著至關重要的作用。這些組織是患者的強力的倡導者，放大患者的聲音並遊說增加胰腺癌研究的資金和資源。透過他們的工作，患者倡導團體不僅提高公眾對胰腺癌的認知，還動員對早期檢測和創新治療方法的支持。此外，我們還促進研究人員、醫療保健專業人員和製藥公司之間的合作，以加速新治療方法的開發並改善患者的治療效果。

治療費用高

高昂的治療費用構成了患者獲得治療的主要障礙，也是胰臟癌市場的主要障礙。由於胰臟癌是一種複雜的疾病，治療時間往往會延長，進一步加重了患者和醫療保健系統的經濟負擔。然而，高昂的醫療費用不僅阻礙患者及時尋求治療，而且還導致醫療預算緊張，並限制了新治療方法研發的資源。

提升手術技術

手術技術的進步正在顯著推動胰臟癌市場的發展，帶來更有效的治療選擇並改善患者的治療效果。與傳統開放性手術相比，腹腔鏡和機器人輔助手術等微創手術可減少術後併發症、縮短恢復時間並提高患者舒適度。這些進步使外科醫生能夠更精確地進行複雜的切除術，並且對周圍組織的損傷最小，從而提高患者的生存率和生活品質。

缺乏早期檢測的生物標記

缺乏用於早期檢測的可靠生物標記是胰臟癌市場發展的主要障礙。與其他癌症不同，生物標記可以幫助早期診斷，胰臟癌通常直到晚期才出現症狀，這使得及時發現變得困難。因此，患者經常被診斷出患有已經轉移的疾病，嚴重限制了治療選擇並降低了整體存活率。由於缺乏有效的生物標記，臨床醫生缺乏在早期、可治療階段識別胰臟癌的方法，阻礙了標靶治療和個人化治療方法的發展。

COVID-19 的影響：

雖然疫情加劇了創新治療的緊迫性並加速了研究工作，但它也擾亂了病患照護和臨床試驗。將醫療資源轉移到管理 COVID-19 上，導致癌症服務緊張，並延遲了許多胰腺癌患者的診斷和治療開始。對不必要的醫療程序的限制以及更少的患者就診醫療機構導致篩檢和診斷程序減少，可能導致胰臟癌的漏診或延遲診斷。然而，大流行刺激了遠端醫療和遠端監控解決方案的採用，為在 COVID-19 限制帶來的挑戰中繼續患者護理和參與臨床試驗提供了途徑。

預計放射線治療產業在預測期內將是最大的

預計放射線治療領域在預測期內將是最大的。這種治療方法使用高能量輻射來破壞癌細胞並縮小腫瘤。對於胰臟癌，手術選擇往往受到最終診斷或腫瘤位置的限制，放射線治療正在成為重要的治療選擇。放射線治療用於在手術前縮小腫瘤，使其更適合手術切除，並在手術後瞄準剩餘的癌細胞。此外，放射線治療通常與其他治療方法（例如化療）結合使用，以最大限度地發揮其療效。

磁振造影（MRI）領域預計在預測期內將呈現最高的複合年成長率。

磁振造影（MRI）領域預計在預測期內複合年成長率最高。 MRI具有優良的軟組織對比度，可以準確地顯示胰臟及周圍結構，有利於胰臟腫瘤的早期發現和準確分期。 MRI 是非侵入性的，不使用電離輻射，這使其特別有利於監測疾病進展和治療效果。此外，擴散加權成像和動態造影MRI 等進步正在進一步提高胰臟癌檢測的敏感度和特異性。

比最大的地區

據估計，亞太地區在估計期間佔據胰腺癌市場的最大佔有率。有效的報銷政策可以促進更多患者獲得昂貴但可能挽救生命的治療，例如化療、放射線治療和手術干預。透過確保醫療費用得到支付，這些政策鼓勵醫療保健提供者採用先進的技術和治療方法，並促進區域內胰腺癌患者護理品質的提高。此外，有利的報銷政策激勵製藥公司投資於針對當地醫療需求的研發，從而推出新型治療方法和診斷工具。

複合年成長率最高的地區：

預計亞太地區在估計和預測期內將實現盈利成長。透過嚴格的法律規範，政府確保製藥公司在開發胰臟癌治療方法時遵守高功效和安全標準。監管機構正在努力加快新治療方法的核准流程，並確保亞太地區的患者能夠及時獲得尖端治療方法。此外，監管促進了市場相關人員之間的透明度和公平競爭，透過以有競爭力的價格提供更廣泛的治療選擇，最終使消費者受益。這些因素正在推動該地區的成長。

提供免費客製化：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球胰臟癌市場：依治療類型

  • 放射治療
  • 標靶藥物治療
  • 免疫療法
  • 化療
  • 其他治療類型

第6章全球胰臟癌市場：依診斷工具分類

  • 電腦斷層掃描 (CT) 掃描
  • 磁振造影(MRI)
  • 正子斷層掃描 (PET) 掃描
  • 其他診斷工具

第7章全球胰臟癌市場：依最終用戶分類

  • 診斷實驗室
  • 醫院
  • 其他最終用戶

第8章全球胰臟癌市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第 10 章 公司概況

  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Midatech Pharma PLC
  • Eli Lilly and Company
  • Sun BioPharma, Inc
  • Oncolytics Biotech
  • Clovis Oncology
  • Polaris Pharmaceuticals, Inc
  • Pharmacyte Biotech Inc
  • Novartis International AG
Product Code: SMRC26261

According to Stratistics MRC, the Global Pancreatic Cancer Market is accounted for $3.42 billion in 2024 and is expected to reach $9.13 billion by 2030 growing at a CAGR of 17.8% during the forecast period. Pancreatic cancer is a malignant neoplasm that originates in the tissues of the pancreas, an organ located behind the stomach. It is characterized by the abnormal and uncontrollable growth of cells in the pancreas, leading to the formation of tumors. Pancreatic cancer is often difficult to detect in its early stages, which contributes to its high mortality rate. Symptoms may not manifest until the disease has progressed significantly, and they can include abdominal pain, jaundice, unexplained weight loss, and digestive issues.

According to the America's Cancer Society for pancreatic cancer, about 64,050 people will be diagnosed with pancreatic cancer in 2023 and estimation of around 50,550 people will die of pancreatic cancer.

Market Dynamics:

Driver:

Active involvement of patient advocacy groups

Active involvement of patient advocacy groups is playing a pivotal role in enhancing the Pancreatic Cancer Market by fostering awareness, driving research initiatives, and influencing policy changes. These groups serve as powerful advocates for patients, amplifying their voices and lobbying for increased funding and resources for pancreatic cancer research. Through their efforts, patient advocacy groups are not only raising public awareness about the disease but also mobilizing support for early detection methods and innovative treatments. Moreover, they facilitate collaboration among researchers, healthcare professionals, and pharmaceutical companies, accelerating the development of novel therapies and improving patient outcomes.

Restraint:

High treatment costs

High treatment costs significantly hinder the Pancreatic Cancer Market by posing a substantial barrier to access for patients. The complexity of the disease often requires prolonged treatment periods, further exacerbating financial burdens on patients and healthcare systems. However, the high costs not only deter patients from seeking timely medical care but also strain healthcare budgets, limiting the availability of resources for research and development of new therapies.

Opportunity:

Improvements in surgical techniques

Improvements in surgical techniques are significantly enhancing the pancreatic cancer market by offering more effective treatment options and better patient outcomes. Minimally invasive procedures, such as laparoscopic and robotic-assisted surgeries, have reduced postoperative complications, shortened recovery times, and improved patient comfort compared to traditional open surgeries. These advancements enable surgeons to perform complex pancreatic resections with greater precision and minimal damage to surrounding tissues, leading to improved survival rates and quality of life for patients.

Threat:

Lack of biomarkers for early detection

The absence of reliable biomarkers for early detection poses a significant obstacle in advancing the pancreatic cancer market. Unlike some other cancers where biomarkers aid in early diagnosis, pancreatic cancer often remains asymptomatic until it reaches advanced stages, making timely detection challenging. Consequently, patients are often diagnosed when the disease has already metastasized, severely limiting treatment options and reducing overall survival rates. Without effective biomarkers, clinicians lack the tools to identify pancreatic cancer in its initial stages when it's more treatable, hindering the development of targeted therapies and personalized treatment approaches.

Covid-19 Impact:

While the pandemic heightened the urgency for innovative treatments and accelerated research efforts, it also disrupted patient care and clinical trials. The diversion of healthcare resources towards managing Covid-19 strained cancer care services, leading to delayed diagnoses and treatment initiation for many pancreatic cancer patients. Restrictions on non-essential medical procedures and reduced patient visits to healthcare facilities resulted in a decline in screening and diagnostic procedures, potentially causing missed or delayed diagnoses of pancreatic cancer. However, the pandemic also prompted the adoption of telemedicine and remote monitoring solutions, offering some avenues for continued patient care and clinical trial participation amidst the challenges posed by Covid-19 restrictions.

The Radiation Therapy segment is expected to be the largest during the forecast period

Radiation Therapy segment is expected to be the largest during the forecast period. This therapy involves the use of high-energy radiation to destroy cancer cells and shrink tumors. In the case of pancreatic cancer, where surgical options are often limited due to late-stage diagnosis or tumor location, radiation therapy emerges as a crucial treatment modality. It can be employed preoperatively to shrink tumors, making them more manageable for surgical removal, or postoperatively to target any remaining cancer cells. Additionally, radiation therapy is often combined with other treatment modalities like chemotherapy to maximize its effectiveness.

The Magnetic Resonance Imaging (MRI) segment is expected to have the highest CAGR during the forecast period

Magnetic Resonance Imaging (MRI) segment is expected to have the highest CAGR during the forecast period. MRI offers superior soft tissue contrast, allowing for precise visualization of the pancreas and surrounding structures, facilitating early detection and accurate staging of pancreatic tumors. Its non-invasive nature and lack of ionizing radiation make it particularly advantageous for monitoring disease progression and treatment response. Moreover, advancements such as diffusion-weighted imaging and dynamic contrast-enhanced MRI have further improved the sensitivity and specificity of pancreatic cancer detection.

Region with largest share:

Asia Pacific region is estimated to hold the largest share of the Pancreatic Cancer Market over the extrapolated period of time. Effective reimbursement policies can facilitate broader patient access to costly yet potentially life-saving treatments such as chemotherapy, radiation therapy, and surgical interventions. By ensuring that healthcare costs are covered, these policies encourage healthcare providers to adopt advanced technologies and therapies, driving regional improvements in the quality of care for pancreatic cancer patients. Moreover, favorable reimbursement policies can incentivize pharmaceutical companies to invest in research and development efforts tailored to the region's specific healthcare needs, leading to the introduction of novel therapies and diagnostic tools.

Region with highest CAGR:

Asia Pacific region is projected to estimate the profitable growth during the forecasted period. Through stringent regulatory frameworks, governments are ensuring that pharmaceutical companies adhere to high standards of efficacy and safety in developing pancreatic cancer treatments throughout the region. Regulatory bodies are working towards expediting the approval process for new therapies, facilitating timely access to cutting-edge treatments for patients in the Asia Pacific region. Additionally, regulations promote transparency and fair competition among market players, which ultimately benefits consumers by offering a wider range of treatment options at competitive prices. These elements are boosting the regional growth.

Key players in the market

Some of the key players in Pancreatic Cancer market include Celgene Corporation, F. Hoffmann-La Roche AG, Midatech Pharma PLC, Eli Lilly and Company, Sun BioPharma, Inc, Oncolytics Biotech, Clovis Oncology, Polaris Pharmaceuticals, Inc, Pharmacyte Biotech Inc and Novartis International AG.

Key Developments:

In March 2023, Novartis is currently in Phase I of the clinical development of LGK-974 for metastatic pancreatic cancer. The phase transition success rate (PTSR) benchmark for moving into Phase II for Phase I drugs for Metastatic Pancreatic Cancer is 88%, according to GlobalData.

In December 2022, scientists developed the world's first early pancreatic cancer screening test, which utilizes worms to discover tumors. The test, which was initiated in Japan this month, claims to be 100% precise in detecting cancer and can trace it in its early stages.

In October 2022, Erasca, based extended its current collaboration with Pfizer to evaluate ERAS-007 when combined with Pfizer's Ibrance (palbociclib). Both biopharma will start clinical proof-of-concept research as part of the extended clinical trial collaboration and supply agreement.

In February 2022, A partnership between Eli Lilly and Company and UNICEF was announced with the goal of enhancing healthcare resources for the roughly 10 million children and adolescents with non-communicable diseases.

Treatment Types Covered:

  • Radiation Therapy
  • Targeted Drug Therapy
  • Immunotherapy
  • Chemotherapy
  • Other Treatment Types

Diagnostic Tools Covered:

  • Computerized Tomography (CT) Scans
  • Magnetic Resonance Imaging (MRI)
  • Positron Emission Tomography (PET) Scans
  • Other Diagnostic Tools

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pancreatic Cancer Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Radiation Therapy
  • 5.3 Targeted Drug Therapy
  • 5.4 Immunotherapy
  • 5.5 Chemotherapy
  • 5.6 Other Treatment Types

6 Global Pancreatic Cancer Market, By Diagnostic Tool

  • 6.1 Introduction
  • 6.2 Computerized Tomography (CT) Scans
  • 6.3 Magnetic Resonance Imaging (MRI)
  • 6.4 Positron Emission Tomography (PET) Scans
  • 6.5 Other Diagnostic Tools

7 Global Pancreatic Cancer Market, By End User

  • 7.1 Introduction
  • 7.2 Diagnostic Laboratories
  • 7.3 Hospitals
  • 7.4 Other End Users

8 Global Pancreatic Cancer Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Celgene Corporation
  • 10.2 F. Hoffmann-La Roche AG
  • 10.3 Midatech Pharma PLC
  • 10.4 Eli Lilly and Company
  • 10.5 Sun BioPharma, Inc
  • 10.6 Oncolytics Biotech
  • 10.7 Clovis Oncology
  • 10.8 Polaris Pharmaceuticals, Inc
  • 10.9 Pharmacyte Biotech Inc
  • 10.10 Novartis International AG

List of Tables

  • Table 1 Global Pancreatic Cancer Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 3 Global Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
  • Table 4 Global Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
  • Table 5 Global Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 6 Global Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 7 Global Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 8 Global Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
  • Table 9 Global Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
  • Table 10 Global Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 11 Global Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
  • Table 12 Global Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
  • Table 13 Global Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
  • Table 14 Global Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 15 Global Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 16 Global Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 17 North America Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
  • Table 18 North America Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 19 North America Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
  • Table 20 North America Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
  • Table 21 North America Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 22 North America Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 23 North America Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 24 North America Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
  • Table 25 North America Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
  • Table 26 North America Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 27 North America Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
  • Table 28 North America Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
  • Table 29 North America Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
  • Table 30 North America Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 31 North America Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 32 North America Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 33 Europe Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
  • Table 34 Europe Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 35 Europe Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
  • Table 36 Europe Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
  • Table 37 Europe Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 38 Europe Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 39 Europe Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 40 Europe Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
  • Table 41 Europe Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
  • Table 42 Europe Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 43 Europe Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
  • Table 44 Europe Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
  • Table 45 Europe Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
  • Table 46 Europe Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 47 Europe Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 48 Europe Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 49 Asia Pacific Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
  • Table 50 Asia Pacific Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 51 Asia Pacific Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
  • Table 52 Asia Pacific Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
  • Table 53 Asia Pacific Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 54 Asia Pacific Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 55 Asia Pacific Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 56 Asia Pacific Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
  • Table 57 Asia Pacific Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
  • Table 58 Asia Pacific Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 59 Asia Pacific Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
  • Table 60 Asia Pacific Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
  • Table 61 Asia Pacific Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
  • Table 62 Asia Pacific Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 63 Asia Pacific Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 64 Asia Pacific Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 65 South America Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
  • Table 66 South America Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 67 South America Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
  • Table 68 South America Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
  • Table 69 South America Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 70 South America Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 71 South America Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 72 South America Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
  • Table 73 South America Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
  • Table 74 South America Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 75 South America Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
  • Table 76 South America Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
  • Table 77 South America Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
  • Table 78 South America Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 79 South America Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 80 South America Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 81 Middle East & Africa Pancreatic Cancer Market Outlook, By Country (2022-2030) ($MN)
  • Table 82 Middle East & Africa Pancreatic Cancer Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 83 Middle East & Africa Pancreatic Cancer Market Outlook, By Radiation Therapy (2022-2030) ($MN)
  • Table 84 Middle East & Africa Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2022-2030) ($MN)
  • Table 85 Middle East & Africa Pancreatic Cancer Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 86 Middle East & Africa Pancreatic Cancer Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 87 Middle East & Africa Pancreatic Cancer Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 88 Middle East & Africa Pancreatic Cancer Market Outlook, By Diagnostic Tool (2022-2030) ($MN)
  • Table 89 Middle East & Africa Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2022-2030) ($MN)
  • Table 90 Middle East & Africa Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
  • Table 91 Middle East & Africa Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2022-2030) ($MN)
  • Table 92 Middle East & Africa Pancreatic Cancer Market Outlook, By Other Diagnostic Tools (2022-2030) ($MN)
  • Table 93 Middle East & Africa Pancreatic Cancer Market Outlook, By End User (2022-2030) ($MN)
  • Table 94 Middle East & Africa Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 95 Middle East & Africa Pancreatic Cancer Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 96 Middle East & Africa Pancreatic Cancer Market Outlook, By Other End Users (2022-2030) ($MN)